Advertisement

Vaccine Design

The Subunit and Adjuvant Approach

  • Michael F. Powell
  • Mark J. Newman

Part of the Pharmaceutical Biotechnology book series (PBIO, volume 6)

Table of contents

  1. Front Matter
    Pages i-xlv
  2. Dale N. Lawrence, Karen L. Goldenthal, John W. Boslego, Donna K. F. Chandler, John R. La Montagne
    Pages 43-60
  3. Jeanine L. Bussiere, George C. McCormick, James D. Green
    Pages 61-79
  4. Lawrence W. Davenport
    Pages 81-96
  5. Patricia E. Fast, Leigh A. Sawyer, Susan L. Wescott
    Pages 97-134
  6. Frederick R. Vogel, Michael F. Powell
    Pages 141-228
  7. Rajesh K. Gupta, Bradford E. Rost, Edgar Relyveld, George R. Siber
    Pages 229-248
  8. Stanley L. Hem, Joe L. White
    Pages 249-276
  9. Gary Ott, Gail L. Barchfeld, David Chernoff, Ramachandran Radhakrishnan, Peter van Hoogevest, Gary Van Nest
    Pages 277-296
  10. Patricia J. Freda Pietrobon
    Pages 347-361
  11. Raphael J. Mannino, Susan Gould-Fogerite
    Pages 363-387
  12. Justin Hanes, Masatoshi Chiba, Robert Langer
    Pages 389-412
  13. Noemi Santiago, Susan Haas, Robert A. Baughman
    Pages 413-438
  14. Jörg Kreuter
    Pages 463-472
  15. Lendon G. Payne, Sharon A. Jenkins, Alexander Andrianov, Bryan E. Roberts
    Pages 473-493
  16. J. Terry Ulrich, Kent R. Myers
    Pages 495-524
  17. Charlotte Read Kensil, Jia-Yan Wu, Sean Soltysik
    Pages 525-541
  18. G. F. Rimmelzwaan, A. D. M. E. Osterhaus
    Pages 543-558
  19. Peter D. Cooper
    Pages 559-580
  20. Michael G. Goodman
    Pages 581-609
  21. Christopher Penney
    Pages 611-624
  22. Penny Dong, Carsten Brunn, Rodney J. Y. Ho
    Pages 625-643
  23. Andrew W. Heath
    Pages 645-658
  24. Lawrence B. Lachman, Li-Chen N. Shih, Xiao-Mei Rao, Stephen E. Ullrich, Jeffrey L. Cleland
    Pages 659-671
  25. Peter J. Kniskern, Stephen Marburg, Ronald W. Ellis
    Pages 673-694
  26. Ronald Eby
    Pages 695-718
  27. Richard T. Coughlin, Jianneng Ma, Daniel E. Cox
    Pages 719-735
  28. Robert B. Grieve, Nancy Wisnewski, Glenn R. Frank, Cynthia A. Tripp
    Pages 737-768
  29. Stephen L. Hoffman, John B. Sacci Jr.
    Pages 787-802
  30. Bernardetta Nardelli, James P. Tam
    Pages 803-819
  31. Robert W. Chesnut, Alessandro Sette, Esteban Celis, Peggy Wentworth, Ralph T. Kubo, Jeff Alexander et al.
    Pages 847-874
  32. Donald A. Harn, Sandra R. Reynolds, Silas Chikunguwo, Steve Furlong, Charles Dahl
    Pages 891-905
  33. Laura L. Snyder, David V. Woo, Pierre L. Triozzi, Vernon C. Stevens
    Pages 907-930
  34. Back Matter
    Pages 931-949

About this book

Introduction

When my interest was first drawn to the phenomenon of vaccination for virus diseases in the late 1930s, the state of the art and the science of vaccine design was not far advanced beyond the time of Jenner at the end of the 18th century and of Pasteur a century later. In the 1930s it was still believed that for the induction of immunity to a virus-caused disease the experience of infection was required, but not for a toxin-caused disease such as diphtheria or tetanus, for which a chemically detoxified antigen was effective for immu­ nization. This prompted the question as to whether it might be possible to produce a similar effect for virus diseases using nonreplicating antigens. When in the 1930s and 1940s it was found possible to propagate influenza viruses in the chick embryo, protective effects could be induced without the need to experience infection by the use of a sufficient dose of a noninfectious influenza virus preparation. Later in the 1940s, it became possible to propagate polio and other viruses in cultures of human and monkey tissue and to immunize against other virus diseases in the same way. Later, with the advent of the era of molecular biology and genetic engineering, antigens and vaccines could be produced in new and creative ways, using either replicating or nonreplicating forms of the appropriate antigens for inducing a dose-related protective state.

Keywords

antigen calcium protein vaccine

Editors and affiliations

  • Michael F. Powell
    • 1
  • Mark J. Newman
    • 2
  1. 1.Genentech, Inc.South San FranciscoUSA
  2. 2.Vaxcel, Inc.NorcrossUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4615-1823-5
  • Copyright Information Plenum Press, New York 1995
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Print ISBN 978-1-4613-5737-7
  • Online ISBN 978-1-4615-1823-5
  • Series Print ISSN 1078-0467
  • Buy this book on publisher's site